Lieve Desbonnet

List of Publications by Year
in descending order

32 papers	3,023 citations	430442 18 h-index	500791 28 g-index
32 all docs	32 docs citations	32 times ranked	4777 citing authors

#	Article	IF	Citations
1	The probiotic Bifidobacteria infantis: An assessment of potential antidepressant properties in the rat. Journal of Psychiatric Research, 2008, 43, 164-174.	1.5	760
2	Gut microbiota depletion from early adolescence in mice: Implications for brain and behaviour. Brain, Behavior, and Immunity, 2015, 48, 165-173.	2.0	572
3	The microbiome: stress, health and disease. Mammalian Genome, 2014, 25, 49-74.	1.0	361
4	Gene Ã— Environment Interactions in Schizophrenia: Evidence from Genetic Mouse Models. Neural Plasticity, 2016, 2016, 1-23.	1.0	265
5	Prenatal stress-induced alterations in major physiological systems correlate with gut microbiota composition in adulthood. Psychoneuroendocrinology, 2015, 60, 58-74.	1.3	224
6	Chronic Adolescent Exposure to Î”-9-Tetrahydrocannabinol in COMT Mutant Mice: Impact on Psychosis-Related and Other Phenotypes. Neuropsychopharmacology, 2010, 35, 2262-2273.	2.8	97
7	Sexually dimorphic effects of maternal separation stress on corticotrophinâ€releasing factor and vasopressin systems in the adult rat brain. International Journal of Developmental Neuroscience, 2008, 26, 259-268.	0.7	88
8	Gestational Stress Leads to Depressive-Like Behavioural and Immunological Changes in the Rat. NeuroImmunoModulation, 2006, 13, 82-88.	0.9	76
9	Phenotypic effects of repeated psychosocial stress during adolescence in mice mutant for the schizophrenia risk gene neuregulin-1: A putative model of gene Ã— environment interaction. Brain, Behavior, and Immunity, 2012, 26, 660-671.	2.0	76
10	Premature responding following bilateral stimulation of the rat subthalamic nucleus is amplitude and frequency dependent. Brain Research, 2004, 1008, 198-204.	1.1	75
11	Genetic vs. pharmacological inactivation of COMT influences cannabinoid-induced expression of schizophrenia-related phenotypes. International Journal of Neuropsychopharmacology, 2012, 15, 1331-1342.	1.0	55
12	Mice mutant for genes associated with schizophrenia: Common phenotype or distinct endophenotypes?. Behavioural Brain Research, 2009, 204, 258-273.	1.2	54
13	Mutant models for genes associated with schizophrenia. Biochemical Society Transactions, 2009, 37, 308-312.	1.6	51
14	Microbial regulation of hippocampal miRNA expression: Implications for transcription of kynurenine pathway enzymes. Behavioural Brain Research, 2017, 334, 50-54.	1.2	44
15	Monopolar versus bipolar high frequency stimulation in the rat subthalamic nucleus: differences in histological damage. Neuroscience Letters, 2004, 367, 92-96.	1.0	42
16	Physiological and behavioural responsivity to stress and anxiogenic stimuli in COMT-deficient mice. Behavioural Brain Research, 2012, 228, 351-358.	1.2	37
17	Prenatal Maternal Paroxetine Treatment and Neonatal Mortality in the Rat: A Preliminary Study. Neonatology, 2008, 93, 52-55.	0.9	30
18	Re: Gut microbiota depletion from early adolescence in mice: Implications for brain and behaviour. Brain, Behavior, and Immunity, 2015, 50, 335-336.	2.0	24

#	Article	IF	Citations
19	Neuregulin-1 signaling in schizophrenia: â€˜Jack of all tradesâ€™ or master of some?. Expert Review of Neurotherapeutics, 2009, 9, 1-3.	1.4	16
20	Epistatic and Independent Effects on Schizophrenia-Related Phenotypes Following Co-disruption of the Risk Factors Neuregulin-1 Ã— DISC1. Schizophrenia Bulletin, 2017, 43, 214-225.	2.3	15
21	Genetically modified mice related to schizophrenia and other psychoses: Seeking phenotypic insights into the pathobiology and treatment of negative symptoms. European Neuropsychopharmacology, 2014, 24, 800-821.	0.3	13
22	Molecular Genetic Models Related to Schizophrenia and Psychotic Illness: Heuristics and Challenges. Current Topics in Behavioral Neurosciences, 2011, 7, 87-119.	0.8	12
23	Modeling schizophrenia: uncovering novel therapeutic targets. Expert Review of Clinical Pharmacology, 2012, 5, 667-676.	1.3	9
24	Mutant Mouse Models in Evaluating Novel Approaches to Antipsychotic Treatment. Handbook of Experimental Pharmacology, 2012, , 113-145.	0.9	8
25	Catechol-O-Methyl Transferase as a Drug Target for Schizophrenia. CNS and Neurological Disorders - Drug Targets, 2012, 11, 282-291.	0.8	6
26	Susceptibility Genes for Schizophrenia: Mutant Models, Endophenotypes and Psychobiology. Current Topics in Behavioral Neurosciences, 2011, 12, 209-250.	0.8	5
27	Altered cytokine profile, pain sensitivity, and stress responsivity in mice with co-disruption of the developmental genes Neuregulin-1Ã—DISC1. Behavioural Brain Research, 2017, 320, 113-118.	1.2	5
28	Acute stress in adolescence vs early adulthood following selective deletion of dysbindin-1A: Effects on anxiety, cognition and other schizophrenia-related phenotypes. Journal of Psychopharmacology, 2019, 33, 1610-1619.	2.0	3
29	Mouse Models of Schizophrenia. Handbook of Behavioral Neuroscience, 2016, 23, 267-284.	0.7	0
30	Ethologically based behavioural and neurochemical characterisation of mice with isoform-specific loss of dysbindin-1A in the context of schizophrenia. Neuroscience Letters, 2020, 736, 135218.	1.0	0
31	Mutant and Transgenic Tools in Modeling Schizophrenia. Neuromethods, 2010, , 217-239.	0.2	0
32	Cannabinoids, Monoamines, COMT and Schizophrenia: Pathobiological Mechanisms in Psychosis. , 2013, , 297-323.		0